_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
Go-ahead for pivotal clinical trial which is expected to commence by March
UCB plans to submit regulatory applications in Q3 2022
Biocon has reported consolidated financial results for the period ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated
